These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 25470699)
21. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824 [No Abstract] [Full Text] [Related]
22. Crizotinib in ROS1-rearranged non-small-cell lung cancer. Arnaoutakis K N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265 [No Abstract] [Full Text] [Related]
24. ROS1--targeting the one percent in lung cancer. Gold KA N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376 [No Abstract] [Full Text] [Related]
25. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564 [No Abstract] [Full Text] [Related]
26. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679 [TBL] [Abstract][Full Text] [Related]
27. Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient. Remon J; Gazzah A; Besse B; Soria JC J Thorac Oncol; 2015 Aug; 10(8):e72-3. PubMed ID: 26200282 [No Abstract] [Full Text] [Related]
28. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Guo L; Zhang H; Shao W; Chen B Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259 [TBL] [Abstract][Full Text] [Related]
29. [Management of crizotinib, a new individualized treatment]. Fallet V; Toper C; Antoine M; Cadranel J; Wislez M Bull Cancer; 2012; 99(7-8):787-91. PubMed ID: 22713522 [TBL] [Abstract][Full Text] [Related]
30. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. Cameron L; Solomon B Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736 [TBL] [Abstract][Full Text] [Related]
31. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Rodig SJ; Shapiro GI Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129 [TBL] [Abstract][Full Text] [Related]